What is claimed is:

1. A compound of having the structure:



wherein

one of R_1 or R_2 is –C(=O)OH and the other of R_1 or R_2 is –C(=O)OR_{13} or –C(=O)O-alkyl-R_{14},

wherein

R_{13} is ~~cycloalkyl, aryl or heteroaryl~~, and

R_{14} is ~~CF_3, cycloalkyl, cycloheteroalkyl, aryl or heteroaryl;~~, and

R_3, R_4, R_5, R_6, R_7, R_8, R_9, R_{10}, R_{11} and R_{12} are each independently, H, -OR_{15} or halogen,

wherein R_{15} is H, $C_{1\text{-}10}$ alkyl~~, $C_{2\text{-}10}$ alkenyl, $C_{2\text{-}10}$ alkynyl, aryl, or heteroaryl~~,

wherein when one of R_1 or R_2 is –C(=O)OH and R_3, R_4, R_5, R_6, R_7, R_8, R_9, R_{10}, R_{11} and R_{12} are each H, then the other of R_1 or R_2 is other than –C(=O)OR_{13} where R_{13} is 1-~~naphthalene~~naphthyl or 2-~~naphthalene~~naphthyl, or –C(=O)O-alkyl-R_{14} where the alkyl is a branched C_2 alkyl and the R_{14} is phenyl,

or an enantiomer or racemate thereof;

or a pharmaceutically acceptable salt thereof.

2. The compound of claim 1 having the structure:



wherein

one of R_1 or R_2 is –C(=O)OH and the other of R_1 or R_2 is –C(=O)OR_{13} or –C(=O)O-alkyl-R_{14},

wherein

R_{13} is cycloalkyl, aryl or heteroaryl, and

R_{14} is CF_3, cycloalkyl, aryl or heteroaryl; and

R_3, R_4, R_5, R_6, R_7, R_8, R_9, R_{10}, R_{11} and R_{12} are each independently, H -OR_{15} or halogen

wherein R_{15} is H, C_{1-10} alkyl, C_{2-10} alkenyl, C_{2-10} alkynyl, aryl, or heteroaryl,

wherein when one of R_1 or R_2 is –C(=O)OH and R_3, R_4, R_5, R_6, R_7, R_8, R_9, R_{10}, R_{11} and R_{12} are each H, then the other of R_1 or R_2 is other than –C(=O)OR_{13} where R_{13} is 1-naphthalene or 2-naphthalene, or –C(=O)O-alkyl-R_{14} where the alkyl is a branched C_2 alkyl and the R_{14} is phenyl,

or an enantiomer or racemate thereof;

or a pharmaceutically acceptable salt thereof.

~~3.~~2. The compound of claim 1~~ or 2~~, wherein when one of R_1 or R_2 is –C(=O)OH and R_3, R_4, R_5, R_6, R_7, R_8, R_9, R_{10}, R_{11} and R_{12} are each H, then the other of R_1 or R_2 is other than –C(=O)OR_{13} where R_{13} is tolyl, 1-~~naphthalene~~naphthyl or 2-~~naphthalene~~naphthyl, or –C(=O)O-alkyl-R_{14} where the alkyl is a branched C_2 alkyl and the R_{14} is phenyl.

~~4.~~3. The compound of claim 1~~ or 2~~, wherein when one of R_1 or R_2 is –C(=O)OH and the other of R_1 or R_2 is –C(=O)OR_{13} where R_{13} is 1-~~naphthalene~~naphthyl or 2-~~naphthalene~~naphthyl, then one of R_3, R_4, R_5, R_6, R_7, R_8, R_9, R_{10}, R_{11} and R_{12} is other than –H; or

wherein when one of R_1 or R_2 is –C(=O)OH and the other of R_1 or R_2 is –C(=O)OR_{13} where R_{13} is 1-~~naphthalene~~naphthyl or 2-~~naphthalene~~naphthyl, then two of R_3, R_4, R_5, R_6, R_7, R_8, R_9, R_{10}, R_{11} and R_{12} ~~is~~are other than –H; or

wherein when one of R_1 or R_2 is –C(=O)OH and the other of R_1 or R_2 is –C(=O)OR_{13} where R_{13} is 1-~~naphthalene~~naphthyl or 2-~~naphthalene~~naphthyl, then four of R_3, R_4, R_5, R_6, R_7, R_8, R_9, R_{10}, R_{11} and R_{12} ~~is~~are other than –H.

~~5.~~4. The compound of ~~any one of claims 1-4~~claim 1,

wherein

~~one of~~ R_1 or R_2 is –C(=O)OR_{13},

~~wherein~~ R_{13} is ~~cycloalkyl, aryl or heteroaryl~~; and

the other of R_1 or R_2 is –C(=O)OH.

~~6.~~5. The compound of ~~any one of claims 1-4~~claim 1,

wherein

~~one of~~ R_1 or R_2 is –C(=O)O-alkyl-R_{14},

~~wherein~~ R_{14} is ~~CF_3, cycloalkyl, aryl or heteroaryl~~; and

the other of R_1 or R_2 is –C(=O)OH.

~~7.~~6. The compound of ~~any one of claims 5 or 6~~claim 4, wherein the aryl ~~or heteroaryl~~ is a substituted aryl~~ or heteroaryl~~, wherein the aryl ~~or~~

~~heteroaryl~~ is substituted with a halogen, ~~–OH,~~ heteroaryl, C_2-C_6 alkynyl, –O(alkyl), amide, aryl or hydroxyaryl.

~~8.~~7. The compound of claim ~~7~~6, wherein the aryl is substituted with a F, Cl, Br, ~~–OH,~~ I, -NHC(O)CH_3, triazolyl, C_2 alkynyl, phenyl, *o*-hydroxyphenyl or –OCH_3.

~~9. The compound of claim 7, wherein the heteroaryl is substituted with a F, Cl, Br, -OH, I, -NHC(O)CH_3, triazolyl, C_2 alkynyl, phenyl, *o*-hydroxyphenyl or –OCH_3.~~

~~10. The compound of any one of claims 5 or 6, wherein the cycloalkyl is a substituted cycloalkyl, wherein the cycloalkyl is substituted with a phenyl or a fused benzo group.~~

~~11.~~8. The compound of ~~any one of claims 1-4~~claim 1, wherein

~~———~~one of R_1 or R_2 is











or



, and

the other of R_1 or R_2 is –C(=O)OH; or

wherein

one of R_1 or R_2 is











or



, and

the other of R_1 or R_2 is –C(=O)OH; or

wherein

one of R_1 or R_2 is

, , , , , , , , ; and

the other of R_1 or R_2 is –C(=O)OH.

~~12.~~9. The compound of ~~any one of claims 1-11~~claim 1, wherein R_3, R_4, R_5, R_6, R_7, R_8, R_9, R_{10}, R_{11} and R_{12} are each independently, -H, ~~–NO_2,~~ halogen or -OR_{15},

wherein R_{15} is ~~–H or~~ C_{1-10} alkyl.

~~13. The compound of any one of claims 1-11, wherein one of R_3, R_4, R_5, R_6, R_7, R_8, R_9, R_{10}, R_{11} and R_{12} is other than –H.~~

~~14.~~10. The compound of ~~any one of claims 1-11~~claim 1, wherein two of R_3, R_4, R_5, R_6, R_7, R_8, R_9, R_{10}, R_{11} and R_{12} are other than –H; or wherein four of R_3, R_4, R_5, R_6, R_7, R_8, R_9, R_{10}, R_{11} and R_{12} are other than –H.

~~15.~~11. The compound of ~~any one of claims 1-11~~claim 1, wherein R_3, R_4, R_6, R_7, R_8, R_9, R_{11} and R_{12} are each –H; and R_5 and R_{10} are each halogen or -OR_{15},

wherein R_{15} is ~~–H,~~ C_{1-10} alkyl~~, C_{2-10} alkenyl, C_{2-10} alkynyl, aryl, or heteroaryl~~; or

wherein R_4, R_5, R_6, R_9, R_{10} and R_{11} are each –H; R_3 and R_{12} are each –H, halogen or -OR_{15}; and R_7 and R_8 are each halogen or -OR_{15},

wherein R_{15} is ~~–H, C_{1-10} alkyl, C_{2-10} alkenyl, C_{2-10} alkynyl, aryl, or heteroaryl~~; or

wherein R_3, R_4, R_7, R_8, R_9 and R_{12} are each –H; and R_5, R_6, R_{10} and R_{11} are each halogen or -OR_{15},

wherein R_{15} is ~~–H, C_{1-10} alkyl, C_{2-10} alkenyl, C_{2-10} alkynyl, aryl, or heteroaryl~~.

~~16. The compound of any one of claims 1-11, wherein R_3, R_4, R_5, R_6, R_8, R_9, R_{10} and R_{1a} are each H; and R_7 and R_{12} are each NO_2.~~

~~17. The compound of claim 1,~~

~~wherein~~

~~one of R_1 or R_2 is C(=O)OH and the other of R_1 or R_2 is C(=O)OR_{13} or C(=O)O-alkyl-R_{14},~~

~~wherein~~

~~R_{13} is cycloalkyl or aryl, and~~

~~R_{14} is CF_3, cycloheteroalkyl or aryl; and~~

~~R_3, R_4, R_5, R_6, R_7, R_8, R_9, R_{10}, R_{11} and R_{12} are each independently, H or -OR_{15},~~

~~wherein R_{15} is H or C_{1-10} alkyl.~~

~~18. The compound of claim 1 having the structure:~~



































or

~~or an enantiomer or racemate thereof;~~

~~or a pharmaceutically acceptable salt thereof.~~

~~19.~~12. The compound of ~~any one of claims 1-18~~claim 1, wherein the compound is the (S,S) enantiomer.

~~20.~~13. The compound of ~~any one of claims 1-18~~claim 1, wherein the compound is the (R,R) enantiomer.

~~21.~~14. A pharmaceutical composition comprising the compound of ~~any one of claims 1-20~~claim 1 and a pharmaceutically acceptable carrier.

~~22. A method of inhibiting the activity of a Fatty Acid Binding Protein (FABP) comprising contacting the FABP with the compound of any one of claims 1-20.~~

~~23. The method of claim 22, wherein the compound inhibits binding of an FABP ligand to the FABP.~~

~~24. The method of claim 23, wherein the FABP ligand is an endocannabinoid ligand, anandamide (AEA) or 2-arachidonoylglycerol (2-AG).~~

~~25.~~15. The composition of claim ~~21~~14, wherein the composition comprises a mixture of enantiomers enriched in (S,S) enantiomer or a mixture of enantiomers enriched in (R,R) enantiomer.

16. The compound of claim 1, wherein R_{13} is substituted phenyl, unsubstituted naphthyl or unsubstituted indanyl,

wherein the substituted phenyl is substituted with phenyl,

or an enantiomer or racemate thereof;

or a pharmaceutically acceptable salt thereof.

17. The compound of claim 1, wherein R_{13} is unsubstituted aryl, or an enantiomer or racemate thereof; or a pharmaceutically acceptable salt thereof.

18. The compound of claim 17, wherein two of R_3, R_4, R_5, R_6, R_7, R_8, R_9, R_{10}, R_{11} and R_{12} are other than –H; or wherein four of R_3, R_4, R_5, R_6, R_7, R_8, R_9, R_{10}, R_{11} and R_{12} are other than –H.

19. The compound of claim 1 having the structure:



,



,



,



,



,



or



,

or an enantiomer or racemate thereof;
or a pharmaceutically acceptable salt thereof.

20. The compound of claim 18 having the structure:


OMe
COOH
OMe,
O
O

,


OMe
COOH
OMe,
O
O

or


Cl
COOH
Cl
O
O

,


OH
O
HO
O
O
HO

or


OH
O
HO
OMe
MeO
O
O
HO

,

or an enantiomer or racemate thereof;
or a pharmaceutically acceptable salt thereof.

21. The compound of claim 5 having the structure:



, 

,



, 

,



,

or an enantiomer or racemate thereof;
or a pharmaceutically acceptable salt thereof.